Ken Uekawa
- Neurology top 2%
- Endocrinology, Diabetes and Metabolism top 5%
- Molecular Biology
- Physiology top 10%
- Cardiology and Cardiovascular Medicine top 10%
- Co-authors
- Yu HasegawaShokei Kim‐MitsuyamaNobutaka KoibuchiKensuke ToyamaTakashi NakagawaDaisuke SuetaMingjie MaBo-Wen Lin
- Topics
- Neuroinflammation and Neurodegeneration Mechanisms (9 papers)Neurological Disease Mechanisms and Treatments (9 papers)Intracranial Aneurysms: Treatment and Complications (8 papers)
- Partner nations
- JapanUnited States
In The Last Decade
Ken Uekawa
45 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 90
- Neurology 491
- Endocrinology, Diabetes and Metabolism 402
- Molecular Biology 370
- Physiology 337
- Cardiology and Cardiovascular Medicine 257
Countries citing papers authored by Ken Uekawa
This map shows the geographic impact of Ken Uekawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ken Uekawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ken Uekawa more than expected).
Fields of papers citing papers by Ken Uekawa
This network shows the impact of papers produced by Ken Uekawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ken Uekawa. The network helps show where Ken Uekawa may publish in the future.
Co-authorship network of co-authors of Ken Uekawa
This figure shows the co-authorship network connecting the top 25 collaborators of Ken Uekawa. A scholar is included among the top collaborators of Ken Uekawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ken Uekawa. Ken Uekawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 6 | |
| 3 | 1 | |
| 4 | 2 | |
| 5 | 40 | |
| 6 | 6 | |
| 7 | 4 | |
| 8 | 79 | |
| 9 | 3 | |
| 10 | 19 | |
| 11 | 114 | |
| 12 | 7 | |
| 13 | 1 | |
| 14 | 31 | |
| 15 | 20 | |
| 16 | 67 | |
| 17 | 51 | |
| 18 | Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic micebreakdown → | 336 |
| 19 | 1 | |
| 20 | 0 |
About Ken Uekawa
Ken Uekawa is a scholar working on Neurology, Neurology and Cellular and Molecular Neuroscience, having authored 46 papers that have together received 1.5k indexed citations. Recurring topics across this work include Neuroinflammation and Neurodegeneration Mechanisms (9 papers), Neurological Disease Mechanisms and Treatments (9 papers) and Intracranial Aneurysms: Treatment and Complications (8 papers). The work is most often cited by research in Neurology (491 citations), Endocrinology, Diabetes and Metabolism (402 citations) and Biological Psychiatry (41 citations). Ken Uekawa has collaborated with scholars based in Japan and United States. Frequent co-authors include Yu Hasegawa, Shokei Kim‐Mitsuyama, Nobutaka Koibuchi, Kensuke Toyama, Takashi Nakagawa, Daisuke Sueta, Mingjie Ma, Bo-Wen Lin, Hiroaki Kusaka and Tetsuji Katayama. Their work appears in journals such as Nature Communications, Nature Neuroscience and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.